Immune-Boosting drug tested to tame seasonal allergies
NCT ID NCT03776643
Summary
This study tested whether a drug called ILT-101 (low-dose IL-2) could reduce allergy symptoms in people allergic to birch pollen. Twenty-four adults received either the drug or a placebo for 36 days to see if it lessened their nasal congestion and other symptoms when exposed to birch pollen in a controlled chamber. The goal was to see if boosting the body's natural immune-regulating cells could provide relief during allergy season.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLERGIC RHINOCONJUNCTIVITIS TO BIRCH POLLEN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CIC Biothérapies - Service de Biothérapies
Paris, Groupe Hospitalier Pitié-Salpêtrière 47 -83 BD de L'hopital, 75013, France
-
Centre d'essais cliniques, ALYATEC
Strasbourg, Environmental Exposure Chamber, Alyatec, 1 Place de L'hôpital, 67000, France
Conditions
Explore the condition pages connected to this study.